Inclusion Criteria:

- Women 18 years of age or older

- Histologically documented adenocarcinoma of the breast, with T2 (T>2.0 cm) N0 or more
advanced disease.

- No evidence of metastatic disease.

- Disease must be clinically or radio-graphically measurable or evaluable.

- Incisional or core needle biopsy, yielding sufficient tissue for histologic
confirmation of adenocarcinoma, hormone receptor analysis and Her2 testing; and
Tiam-1 expression.

- Subjects may have received no prior chemotherapy for breast cancer. Subjects may have
received up to 3 months of neoadjuvant hormonal therapy, provided they have been
re-staged and are still eligible for this study, and have been off hormonal therapy
at least 48 hours.

- Subject must be Her-2 negative.

- Performance status 0-1 by the ECOG scale.

- Baseline laboratory values must be as follows: Absolute granulocyte count: greater
than 1400/cells/ml; Platelets: greater than 100,000 cells/ml; Total bilirubin: less
than 1.5 mg/dl; Serum ALT: less than 2.5 x institutional upper normal limit;
Creatinine: less than 1.6mg/dl; Hemoglobin: greater than 9.0g/dl

- Subjects must be nonpregnant and nonlactating. Subjects of childbearing potential
must utilize an effective method of contraception during the study.

Exclusion Criteria:

- Subjects who have received chemotherapy or more than 3 months of neoadjuvant hormone
therapy for this cancer.

- Subjects with metastatic disease (disease beyond the breast, axillary nodes and
ipsilateral supraclavicular nodes) or inflammatory breast cancer (T4d).

- Subjects with other active cancers, except non-melanoma skin cancers

- Subjects with an active serious infection or other serious underlying medical
condition that would otherwise impair their ability to receive protocol treatment.

- Dementia or significantly altered mental status that would prohibit comprehension of
or giving of informed consent.

- Pregnant or breast-feeding women; sexually active, pre-menopausal women not willing
to use adequate methods of birth control.

- Subjects who are Her 2 neu positive are excluded.